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1. Introduction
Peripheral artery disease is a clinical manifestation of atherosclerosis with significant morbid‐
ity and mortality (Sharma Sharma & Aronow, 2012; Resnick et al. 2004; Diehm et al. 2009).
Despite well-recognized significance of traditional risk factors in the initiation and progression
of the disease, not all causes and mechanisms leading to disease development have been
identified so far. Inflammation, angiogenesis, and endothelial activation are important
processes contributing to the pathogenesis of peripheral arterial disease which are related in
a complex and interdependent manner (Li et al., 2007; Brevetti et al., 2010; Brevetti Get al.,
2003; Brevetti et al., 2008; Findley et al., 2008).
Pathophysiologic events in peripheral artery disease are represented by ishaemic tissue
damage, and the severity of clinical presentation depends on the site and extent of stenosis
and availability of collateral circulation (Meru et al., 2006; Cooke 2008). Angiogenesis and
arteriogenesis (collateral growth) are different forms of vessel growth, which contribute to the
compensation for an occluded artery. Hypoxia is known to trigger angiogenesis in the setting
of ischaemia, whereas fluid shear stress might be the most important stimulus for initiation of
collateral growth. Besides these specific initial triggers, angiogenesis and collateral growth
share growth factors, chemokines, proteases, and inflammatory cells, which play different
roles in promoting and refining these processes ( Silvestre et al., 2008).
During an tissue ischemia,  hypoxia-inducible factor 1 (HIF-1)  drives transcriptional  acti‐
vation of hundreds of genes involved in vascular reactivity, angiogenesis,  arteriogenesis,
the  mobilization  of  bone  marrow-derived  angiogenic  cells  (Rey  &  Semenza  2010).  The
current  evidence  suggests  considerable  overlap between the  molecular  mechanisms and
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physical  stimuli  that trigger angiogenesis and inflammation (Costa et  al.,  2007).  Further‐
more, there is compelling evidence that HIF-1 contributes to both processes by regulating
angiogenesis  and  functions  of  inflammatory  cells.  Many  inflammatory  stimuli  can  acti‐
vate the angiogenic programme of endothelial cells. Inflammatory cells, especially mono‐
cytes/macrophages  secrete  many angiogenic  factors  such as  vascular  endothelial  growth
factor (VEGF), CXCL8 (interleukin-8), granulocyte colony stimulating factor, transforming
growth factor-α and β, platelet-derived growth factor, tumor necrosis factor-α, and pros‐
taglandins. The angiogenic factors bind to cognate receptors which are expressed on the
surface  of  vascular  endothelial  cells  and  vascular  pericytes/smooth  muscle  cells.  Recep‐
tor–ligand interaction activates  these  cells  and promotes  the  angiogenic  response.  Com‐
munication  between  endothelial  cells  and  monocytes/macrophages  appears  to  be
bidirectional,  because  endothelial  cell–secreted  factors  also  induce  chemotaxis  and  in‐
creased angiogenic activity in monocytes/macrophages, thus initiating a positive feedback
cycle (Shireman, 2007).
The angiogenesis are tightly regulated in a complex balance between pro- and anti-angiogenic
mechanisms (Carmeliet, 2003; Otrock et al., 2007). The most important proangiogenic growth
factors are VEGF and angiopoietins. VEGF and angiopoietins, acting as the modulators of
endothelial activation via receptor tyrosine kinase Tie-2, are important for angiogenesis and
vascular remodeling. VEGF increases microvascular permeability and induces the prolifera‐
tion, migration, and differentiation of endothelial cells (Hoeben et al., 2009; Stuttfeld &,
Ballmer-Hofer, 2009; Olsson et al., 2006). Angiopoietin-2 is a natural endogenous antagonist
of the Tie-2, which acts as an autocrine negative regulator of endothelial function (Augustin
et al., 2009; Scharpfenecker et al., 2004; Fiedler & Augustin, H2006; Fukuhara et al., 2010). In
the presence of VEGF, it mounts an inflammatory response by endothelial activation and
induction of permeability, and in the absence of VEGF, it destabilizes the existing vessels and
leads to vascular regression. Soluble receptors of angiogenic growth factors which are being
released to circulation can act as the inhibitors of angiogenesis and, in some cases, may correlate
with the disease severity independently of altered haemodynamics (Findley et al., 2008).
The findings of the large prospective investigations have confirmed the significance of high-
sensitivity C-reactive protein (hs-CRP) as a marker of progression, functional activity, and
adverse cardiovascular outcome in patients with peripheral artery disease (Abdellaoui & Al-
Khaffaf, 2007).
Platelet activating factor acetylhydrolase (PAF-AH; E.C. 3.1.1.47) also named lipoprotein-
associated  phospholipase  A(2)  (Lp-PLA(2))  is  a  novel  inflammatory  biomarker  that  has
an active role in atherosclerotic development and progression. This enzyme is character‐
ized by its  ability  to  specifically  hydrolyze  the  short  acyl  group at  the  sn-2  position of
the phospholipids in oxidized LDL, which leads to production of the pro-inflammatory,
atherogenic  by-products  lysophosphatidylcholine  and  oxidized  nonesterified  fatty  acids.
These bioactive lipid mediators act as chemoattractants for monocytes, impair endothelial
function,  disrupt  plasma membranes,  and induce  apoptosis  in  smooth muscle  cells  and
macrophages. Epidemiologic studies demonstrate that elevated circulating levels of PAF-
AH predict an increased risk of myocardial infarction and stroke, whereas histologic ex‐
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amination of diseased human coronary arteries reveals intense presence of the enzyme in
atherosclerotic  plaques  that  are  prone to  rupture.  The biological  role  of  PAF-AH in the
development of  peripheral  arterial  disease is  controversial  because substrates  and prod‐
ucts  of  the  catalytic  reactions  implicating  PAF-AH  have  proatherogenic  properties  (Za‐
lewski &, Macphee, 2005; Gazi et al.,  2005; Srinivasan & Bahnson, 2010; Tsimikas et. Al.,
2007; Münzel & Gori, 2009; Ballantyne et al., 2007; Daniels et al., 2008; Garza et al., 2007;
Koenig et al., 2004).
The hypothesis set out in this investigation is that PAF-AH, as a novel biomarker of inflam‐
mation, and VEGF, Ang-2, and its receptor Tie-2, as new biomarkers of angiogenesis, play a
significant role in the development and progression of peripheral artery disease. The aim of
this study was to investigate the association of the catalytic concentrations of platelet activating
factor acetylhydrolase (PAF-AH), the concentrations of VEGF, angiopoietin 2 (Ang-2) and its
receptor Tie-2 (tyrosine kinase with immunoglobulin and epidermal growth factor homology
domains), as novel biomarkers of inflammation and angiogenesis with the lipid status and
CRP, as a nonspecific marker of inflammation and cardiovascular risk factor in patients with
peripheral arterial disease and matched control group. In the group of patients with peripheral
arterial disease, the relationship between the biochemical parameters under study and the
anatomical extent of peripheral arterial atherosclerotic changes, will be explored, and those
will be evaluated through their potential clinical utility as novel diagnostic and prognostic
tools in peripheral arterial atherosclerosis.
2. Patients and methods
2.1. Patients
The study included 110 patients, 19 women and 91 men, with clinically and angiographically
confirmed diagnosis of peripheral arterial disease. The study population was referred to the
Digital subtraction angiography (DSA) in order to determine the precise extent and localization
of peripheral limb atherosclerosis and assess the technical possibility to perform percutaneous
transluminal angioplasty (PTA). Based on the angiographic findings, for the purpose of the
present investigation the angiographic score was assessed for each patient. The angiographic
score takes into consideration the extent (percentage of vessel lumen reduction) and diffusion
of peripheral arterial disease (involved segments of vascular tree). The distal aorta plus 10
segments (common iliac artery, external iliac artery, common femoral artery, profunda femoral
artery, superficial femoral artery, popliteal artery, truncus tibiofibularis, anterior tibial artery,
posterior tibial artery and fibular artery) on each side were scored on the basis of vessel lumen
reduction: 1 if stenoses involved a reduction in the vessel lumen of <50%, 2 if stenoses involved
50 to 99% reduction, and 3 if total occlusion was present. The sum of the points assigned to
each of these arteries was called the angiographic score.
The control group consisted of 118 patients, 61 female and 57 male with suspected symptoms
of peripheral arterial disease referred to Doppler examination. At the Doppler examination,
all of them had normal triphasic waveforms of the peripheral arteries.
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All Doppler and DSA procedures were performed at the Institute for Diagnostic and Inter‐
ventional Radiology of the Merkur University Hospital. Doppler examinations were per‐
formed at a center of excellence with more than 3,000 examinations performed per year. DSA
was performed by an experienced vascular interventional radiologist. All participants gave
their informed written consent. This study was approved by the Ethics Committee of the
Merkur University Hospital, Zagreb, Croatia.
2.2. Samples
Blood samples were taken under controlled pre-analytical conditions in the morning after 12-
h fast. Serum was separated by centrifuging the samples at 4°C at 3000 rpm for 15 minutes.
2.3. Methods
2.3.1. The lipid status and CRP
Analytical methods for measurement of the lipid status, including serum triglyceride, total
cholesterol, LDL and HDL-cholesterol concentrations as well as CRP used in this study have
been accredited according to ISO 15189, Medical laboratories - Particular requirements for
quality and competence (ISO 15189, 2008) (Flegar-Meštrić et al., 2010). All measurements were
performed on fresh sera on the day of blood collection using standard commercial kits
(Olympus Diagnostic GmbH, Hamburg, Germany) on the Olympus AU 600 analyzer (Olym‐
pus Mishima Co., Ltd., Shizuoka, Japan). Serum triglyceride and total cholesterol were
measured by enzymatic PAP- method. HDL cholesterol was measured with direct method
based on selective inhibition of the non-HDL fractions by means of polyanions. A homogene‐
ous assay for the selective measurement of LDL cholesterol in serum was used. The index of
atherosclerosis and the established risk factor were calculated as the ratio of LDL cholesterol
to HDL cholesterol and total cholesterol to HDL cholesterol. CRP concentrations were
determined by high-sensitivity latex-enhanced immunoturbidimetric assay.
2.3.2. The catalytic concentrations of PAF-AH
The catalytic concentrations of PAF-AH were determined in serum by spectrophotometric
method described by Kosaka T. et al. (2000) using the AZWELL Auto PAF-AH Assay Kits
(AZWELL Inc., Osaka, Japan) on a biochemical analyzer Olympus AU600 (Olympus Mishima
Co., Ltd., Shizuoka, Japan). Serum samples were kept frozen at -80°C until the day of analysis.
PAF-AH hydrolyzes the sn-2 position of the substrate (1-myristoyl-2-(4-nitrophenylsuccinyl)
phosphatidylcholine), producing 4-nitrophenyl succinate. This compound immediately
degrades in aqueous solution and liberates 4-nitrophenol. In the first phase, 2 μL of serum was
added to 240 μL of 200 mmol/L HEPES (N-2-hydroxyethylpiperazine–N´-2-ethanesulfonic
acid) buffer (Reagent 1), pH 7.6 and pre-incubated at 37ºC for 5 min. The reaction was started
by adding 80 μL of 20 mmol/L citric acid monohydrate buffer, pH 4.5 containing 90 mmol/L
1-myristoyl-2-(4-nitrophenylsuccinyl)phosphatidylcholine (Reagent 2). The liberation of 4-
nitrophenol was measured by reading differences in absorbance at 405 nm (main wavelength)
and 505 nm (subwavelength) between 1 and 3 minutes after addition of the substrate. The
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catalytic concentrations of PAF-AH are expressed in international units per liter of serum and
standardized against concentration of LDL-cholesterol.
2.3.3. The concentrations of angiogenesis biomarkers: VEGF, Ang-2 and Tie-2 receptor
Commercially available ELISA kits for VEGF (DVE00), Ang2 (DANG 20) and Tie2 (DTE 200)
were purchased from R&D Systems (Minneapolis, MN, USA) and used according to the
manufacturer’s instruction. Serum samples were kept frozen at -80°C until the day of analysis.
Briefly, the microtitre plates were coated with monoclonal antibodies specific for either VEGF-
A, Ang-2 or Tie-2 and the first step was to add standards and samples to the wells. During the
following incubation period, the VEGF-A, Ang-2 or Tie-2 present in standards and samples
were bound to the immobilized antibody. After a thorough wash, an a horseradish peroxidase-
linked polyclonal antibody specific for VEGF, Ang-2 or Tie-2 was pipetted into the wells and
following a second incubation and wash step a substrate solution was added and colour
developed in proportion to the amount of VEGF-A, Ang-2 or Tie-2. After further washings to
remove any unbound antibody–enzyme reagent, tetramethylbenzidine was added. The colour
development was subsequently stopped and the intensity of colour was measured by using
Stat Fax®2100, Microplate reader, Awareness Technology Inc., Palm City, FL, USA. The values
were calculated using a standard curve generated with specific standards provided by the
manufacturer. The detection limit for VEGF, Ang-2 and Tie-2 was 9 ng/L, 8,3 ng/L, and 14 ng/
L, respectively. The intra-assay and interassay coefficients of variation were in the range given
by the manufacturer <6,7% and <8,8% for VEGF, < 6,9% and <10,4% for Ang-2 and< 5,3% and
<8,5% for Tie-2 receptor.
2.4. Statistical analysis
Statistical analyses were performed using the SPSS software package for Windows, version 13
(SPSS Inc, Chicago, IL, USA). Descriptive analyses were performed and data were presented
as mean, median, S.D. and percentile. Normal distribution of the study variables was tested
using Kolmogorov–Smirnov test. Student t test and Mann-Whitney U test or the Kruskal–
Wallis test applied according to the normal or non-normal distribution. Spearman coefficient
of correlation was calculated to evaluate relationships between different variables.
3. Results
3.1. Patients
Demographic and clinical characteristics of the participants are shown in Table 1.
3.2. The lipid status and CRP
The patients had significantly higher concentrations of CRP, triglyceride, index of atheroscle‐
rosis, the ratio of total and HDL cholesterol, and lower concentrations of total, LDL and HDL-
cholesterol (Table2).
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Parameter Patients with PAD
(N=110)
Control subjects
(N=118) P
Age (years), x±sd 64,33 ± 9,79 59,11± 7,31 P<0,001
Male sex, n (%) 91 (83%) 57 (48%) P<0,001
Body mass index (kg/m2), x±sd 26,63 ± 4,04 26,51± 3,08 P = 0,795
Systolic blood pressure >140 mm Hg, n(%) 74 (67%) 0 P<0,001
Diastolic and systolic blood pressure >90 mm
Hg, n (%) 30 (27%) 0 P<0,001
Diabetes, n (%) 39 (35%) 0 P<0,001
Active smokers, n (%) 49 (45%) 13 (11%) P<0,001
Hypolipemic therapy, n (%) 64 (58%) 0 P<0,001
Antihypertensive therapy, n (%) 69 (63%) 0 P<0,001
Cerebrovascular simptoms, (%) 11 (10%) 0 P<0,001
Coronary artery disease symptoms, n (%) 26 (24%) 0 P<0,001
Table 1. Demographic and clinical characteristics of the study groups: patients with peripheral arterial disease (PAD)
and controls. Data are given as mean ± standard deviation, unless otherwise stated.
Biochemical parameters
(units)
Patients with PAD
(N=110)
Control subjects
(N=118) P
Triglyceride (mmol/L) 1,89 (1,30-2,36) 1,42 (1,03-1,76) <0,001
Total cholesterol (mmol/L) 5,45 (4,68-6,10) 6,35 (5,66-6,89) <0,001
HDL-cholesterol (mmol/L) 1,10 (0,98-1,30) 1,60 (1,39-1,81) <0,001
LDL- cholesterol (mmol/L) 3,30 (2,70-3,90) 3,96 (3,40-4,55) <0,001
CRP (mg/L) 3,70 (1,78-7,40) 1,40 (0,60-2,43) <0,001
Mann–Whitney's tests
Table 2. The lipid status and CRP concentrations in the patients with peripheral arterial disease (PAD) and controls.
Data are given as median (interquartile range).
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3.3. The catalytic concentrations of PAF-AH
The catalytic concentrations of PAF-AH did not differ between the two groups, while LDL
standardized catalytic concentrations of PAF-AH (U/mmol) showed significant difference
(Table 3). The catalytic concentrations of PAF-AH were higher in men than in women in control
subjects (Table 4.), whereas no gender difference was observed in patients with peripheral
arterial disease (Table 5.).
A significant difference in the catalytic concentrations of PAF-AH was found between subjects
on lipolythic therapy and subjects off therapy (P=0,032), with the median concentration of PAF-
AH in subjects off therapy being higher than that observed in subjects on lipolythic therapy:
425, interquartile range 351-494 U/L vs 364, interquartile range, 316-427 U/L. There was no
difference in catalytic concentrations of PAF-AH between smokers and non-smokers, diabetic
and nondiabetic subjects nor between the subjects on antihypertensive therapy and subjects
off therapy.
A statistically significant correlation was found between the catalytic concentration of PAF-
AH and the concentration of triglycerides, total and LDL-cholesterol in both groups studied
(Table 6.).
Biochemical parameters (units) Patients with PAD(N=93)
Control subjects
(N=64) P
PAF-AH (U/L) 405 (330-471) 406 (359-479) 0,591
PAF-AH/LDL (U/mmol ) 121 (107-139) 98 (86-120) <0,001
Mann–Whitney's tests
Table 3. The catalytic concentrations of PAF-AH in the patients with peripheral arterial disease (PAD) and control
subjects. Data are given as median (interquartile range).
Biochemical parameters (units) Male(N=28)
Female
(N=36) P
PAF-AH (U/L) 459 (383- 519) 385 (319-437) 0,005
PAF-AH/LDL (U/mmol ) 121 (95-137) 92 (79-103) <0,001
Mann–Whitney's tests
Table 4. The catalytic concentrations of PAF-AH in the male and female control subjects. Data are given as median
(interquartile range).
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Biochemical parameters (units) Male(N=75)
Female
(N=18) P
PAF-AH (U/L) 405 (331- 477) 409 (329-442) 0,722
PAF-AH/LDL (U/mmol ) 123 (108-141) 110 (100- 119) 0,031
Mann–Whitney's tests
Table 5. The catalytic concentrations of PAF-AH in male and female patients with peripheral arterial disease. Data are
given as median (interquartile range)..
Correlation coefficient
Patients with PAD
(N=93)
Control subjects
(N=64)
r P r P
Triglyceride (mmol/L) 0,33 0,001 0,41 0,001
Total cholesterol (mmol/L) 0,70 <0,001 0,32 0,010
HDL-cholesterol (mmol/L) -0,22 0,035 -0,33 0,009
LDL- cholesterol (mmol/L) 0,70 <0,001 0,33 0,009
CRP (mg/L) -0,09 0,371 -0,06 0,617
Table 6. Relationships between the catalytic concentrations of PAF-AH and serum lipids parameters and CRP
concentrations in the study groups: patients with peripheral arterial disease (PAD) and controls
3.4. Serum VEGF, Ang-2 and Tie-2 concentrations
The concentration of VEGF did not differ significantly between groups (Figure 1., Table 7.).
The patients had higher concentrations of Ang-2 and Tie-2 receptor. (Figure 2.,3., Table 7.).
A significant difference in the concentrations of VEGF was found between diabetic and
nondiabetic subjects (P= 0,006), with the median (interquartile range) concentration of VEGF
in diabetics being higher than that observed in nondiabetic subjects: 358 (210-463) vs. 197
(130-335) ng/L. There was no difference in concentrations of VEGF, Ang-2, and Tie-2 receptor
between smokers and non-smokers, nor between the subjects on lipolythic and antihyperten‐
sive therapy and subjects off therapy. All three serum biomarkers of angiogenesis correlated
with the CRP concentrations (Table 8). The concentrations of HDL- cholesterol, VEGF, Ang-2,
and Tie-2 were statistically significantly different among the subjects with various cardiovas‐
cular risk according to CRP concentrations (Table 9.). Post hoc tests (Mann–Whitney's test)
suggested a significant difference in HDL -cholesterol values between the low risk subjects
(CRP<1,0 mg/L) compared with the moderate (CRP between 1,0-3,0 mg/L) (P=0,004) and high
risk (P=0,011) subjects (CRP >3,0 mg/L). The subject groups of moderate and high cardiovas‐
cular risk did not differ significantly in the HDL cholesterol concentration (P=0,666). Statisti‐
cally significant difference was found in the concentrations of VEGF (P=0,011), Ang-2 (P<0,001),
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and Tie-2 receptor (P=0,005) between low and high risk subjects, as well as in the concentrations
of VEGF (P=0,012), Ang-2 (P<0,001), and Tie-2 receptor (P=0,02) between the moderate and
high cardiovascular risk subjects, whereas there were no statistically significant differences in
the concentrations of VEGF (P=0,377), Ang-2 (P=0,438), and Tie-2 receptor (P=0,673) between
the groups of low and moderate cardiovascular risk subjects.
Biochemical parameters (units) Patients with PAD(N=110)
Control subjects
(N=54) P
VEGF (ng/L) 263 (142-403) 287 (115-483) 0,983
Ang-2 (ng/L) 2018 (1613-2689) 1603 (1452-2138) 0,001
Tie-2 (μg/L) 21,4 (18,6-23,9) 19,6 (18,1-22,2)* 0,049
Mann–Whitney's tests, *N=43
Table 7. Biochemical parameters in the patients with peripheral arterial disease (PAD) and controls. Data are given as
median (interquartile range)..
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Figure 1. Comparison of VEGF concentrations (median, interquartile range) in the patients with peripheral arterial dis‐
ease (PAD) and control subjects.
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Figure 2. Comparison of Ang-2 concentrations (median, interquartile range) in the patients with peripheral arterial
disease (PAD) and control subjects.
Biochemical parameters (units) VEGF( ng/L) Ang-2 (ng/L) Tie-2 (μg/L)
r P r P r P
Triglyceride (mmol/L) 0,01 0,955 -0,07 0,489 0,02 0,861
Total cholesterol (mmol/L) -0,13 0,182 -0,02 0,839 0,08 0,424
HDL-cholesterol (mmol/L) -0,26 0,006 -0,14 0,134 0,03 0,735
LDL- cholesterol (mmol/L) -0,05 0,581 0,01 0,955 0,01 0,909
CRP (mg/L) 0,45 <0,001 0,36 <0,001 0,25 0,008
Table 8. Spearman coefficient of correlation between the lipid profile, CRP and biomarkers of angiogenesis in patients
with peripheral arterial disease (n=110).
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Figure 4. Correlation between serum concentrations of VEGF and CRP in patients with peripheral arterial disease.
Sperman coefficient of correlation r= 0,45; P<0,001.
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Figure 3. Comparison of Tie-2 concentrations (median, interquartile range) in the patients with peripheral arterial dis‐
ease (PAD) and control subjects.
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Figure 5. Correlation between serum concentrations of Ang-2 and CRP in patients with peripheral arterial disease.
Sperman coefficient of correlation r= 0,36; P<0,001.
Figure 6. Correlation between serum concentrations of Tie-2 and CRP in patients with peripheral arterial disease.
Sperman coefficient of correlation r= 0,25; P=0,008.
3.5. The relationship between the biochemical parameters under study and the anatomical
extent of peripheral arterial atherosclerotic changes
None of the biochemical parameters investigated correlated with the angiographic score as a
measure of the anatomic extent of atherosclerotic alterations in the peripheral arteries.
(Table 10). From among the traditional risk factors, only the subject age correlated significantly
with the angiographic score (r=0.33; P<0,001). The patients with diabetes had a statistically
Current Trends in Atherogenesis108
significant increase in the score compared with nondiabetic subjects (13.77 ± 6.67 compared
with 11.02 ± 5.50; P=0,023).
Biochemical parameters (units)
Angiographic score
r P
Triglyceride (mmol/L) -0,13 0,167
Total cholesterol (mmol/L) -0,14 0,156
HDL-cholesterol (mmol/L) 0,06 0,539
LDL- cholesterol (mmol/L) -0,12 0,208
CRP (mg/L) 0,07 0,461
VEGF (ng/L) 0,08 0,406
PAF-AH (U/L) -0,08 0,450
Ang-2 (ng/L) 0,04 0,684
Tie-2 (μg/L) 0,13 0,171
Table 10. Spearman coefficient of correlation between the biochemical parameters and angiographic score in
patients with peripheral arterial disease (n=110).
Biochemical parameters
(units)
Patients with PAD (N=110)
P
low risk moderate risk high risk
Triglyceride (mmol/L) 1,59(1,32-2,21)
1,97
(1,39-2,40) 0,87 (1,19-2,38) 0,674
Total cholesterol (mmol/L) 5,60(4,50-6,00)
5,55
(4,83-6,10) 5,40 (4,50-6,00) 0,732
HDL-cholesterol (mmol/L) 1,40(1,10-1,60)
1,10
(0,93-1,30) 1,10 (0,90-1,30) 0,017
LDL- cholesterol (mmol/L) 3,40(2,40-3,80)
3,45
(2,80-4,18) 3,20 (2,70-3,90) 0,549
VEGF (ng/L) 167(88-234)
197
(100-319)
332
(170-504) 0,002
Ang-2 (ng/L) 1663(1379-2279)
1803
(1527-2216)
2256
(1707-3185) 0,003
Tie-2 (μg/L) 18,7(17,5-22,3)
20,4
(17,7-23,4)
22,4
(19,5-25,2) 0,018
PAF-AH (U/L) 350 (294-458) 417 (355-468) 399 (322-480) 0,452
Table 9. Biochemical parameters in the patients with peripheral arterial disease (PAD) according to CRP
concentrations as a cardiovascular risk marker. Levels of CRP below 1mg/L are considered low; levels of 1 - 3 mg/L are
considered moderate and levels greater than 3 mg/L are considered high risk. Data are given as median (interquartile
range).
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4. Discussion
Peripheral artery disease is a systemic manifestation of atherosclerosis with significant
morbidity and mortality. Pathophysiological processes implicated in the development,
progression, and complications of the disease are complex and interdependent and include
interactions between genetic and environmental factors. Pathophysiological events associated
with peripheral artery disease include tissue ischaemia, and the severity of clinical presentation
is dependent of the site and extent of peripheral arterial stenotic-occlusive changes and the
availability of collateral circulation. Ischaemia incites a cascade of biochemical reactions,
leading directly or indirectly to endothelial homeostasis disturbance. Dysfunctional endothe‐
lium is incapable of maintaining adhesiveness coagulation neutrality within the circulating
blood, or regulating tonic arterial activity. In addition to disturbing vessel movements and
promoting atherosclerosis formation, endothelium actively modulates the architecture of
already present atherosclerotic plaques and increases vulnerability of the lesions which thus
become prone to rupture and lead directly to the development of thromboembolic incidents.
The role of the new biomarkers of inflammation, thrombosis, lipoprotein metabolism and
oxidative stress, which are involved in the regulation of vascular homeostasis, is under an
intensive investigation aimed at earlier detection and better understanding of the aetiology
and progression of peripheral artery disease, as well as development of new therapeutic
possibilities.
The catalytic concentrations of PAF-AH did not differ significantly between the subjects and
the control group, contrary to their standardized catalytic concentrations (PAF-AH/LDL)
which were statistically significantly higher (<0,001) in the subjects analyzed compared with
the control group. The catalytic levels of PAF-AH were significantly different between the
genders in the control group, females (n=36) having lower values than males (n=28), which is
consistent with the literature data (Winkler et al., 2005; Iribarren, 2010). Moreover, females also
had lower PAF-AH standardized catalytic concentrations in both groups studied. Changes in
the PAF-AH catalytic levels depend on the concentrations of lipid status parameters, whereat
the PAF-AH catalytic concentrations show a statistically significant positive correlation with
the concentration of triglicerides, total and LDL cholesterol, the atherosclerosis index, and the
total/HDL cholesterol ratio. Statistically significant negative correlation was found between
the catalytic concentration of PAF-AH and the concentration of HDL cholesterol in the control
group, which is consistent with literature data (Winkler et al., 2005; Flegar-Meštrić et al.,
2003; Kamisako et al., 2003; Flegar-Meštrić et al., 2008; Flegar-Meštrić et al, 2012). PAF-AH
catalytic levels did not correlate with the CRP concentration in either of the groups examined.
The results of the present study are consistent with our previous results obtained for the
patients with lesions of the cerebral arteries (Flegar-Meštrić et al., 2003; Flegar-Meštrić et al.,
2008; Flegar-Meštrić et al., 2012). However, in this investigation, we failed to confirm our
previous results in 182 patients with peripheral arterial disease in whom PAF-AH catalytic
concentrations were significantly higher compared with the control group (Perkov et al.,
2010). The differences in the results obtained can be explained by the differences in the number
of patients included in the analysis. Furthermore, the PAF-AH catalytic concentrations are in
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a significant positive correlation with the concentrations of triglicerides, total and LDL
cholesterol. Thus, changes in enzymatic acitivities may also result from the changed concen‐
trations of lipid parameters, particularly if standardized catalytic PAF-AH concentrations are
observed in relation to LDL cholesterol.
The development of vascular endothelial dysfunction is a key mechanism linking the risk
factors and atherosclerosis, and it plays an important role in the pathophysiology of peripheral
artery disease ( Brevetti et al., 2010). Vascular remodeling, as an adaptive response to haemo‐
dynamic and biochemical stressors, is characterized by progressive structural and functional
alterations in blood vessel walls, preceding the development of a cardiovascular disease.
Recent investigations suggest that a crucial role in the regulation of vascular homeostasis is
played by the Tie ligand receptor system. Some smaller scale clinical trials have revealed that
the concentrations of Ang-2, Tie-2, or both, are found in the patients with peripheral arterial
disease (Findley et al., 2008), congestive heart failure (Chong et al., 2004), acute coronary
syndrome (Lee et al., 2004), hypertension (Lim et al., 2004), and that they have a predictive
ability for myocardial infarction (Patel et al., 2005).
In our investigation, the serum concentrations of Ang-2 and its tyrosine kinase receptor, Tie-2,
in the subjects analyzed were statistically significantly higher compared with those in the
control subjects, which is in agreement with the results by Findley et al., (2008) (8). However,
contrary to their results, the VEFG concentrations were not found to be statistically signifi‐
cantly different between our groups. The above mentioned differences in the results may be
accounted for by the great biological variability observed for VEGF. In fact, it is well known
that interindividual and intraindividual variability of VEFG differ significantly depending on
the kind of material used. Analysis samples include serum, whole blood, and plasma. The
intraindividual variation of VEGF in serum, plasma, and whole blood is 10.7%, 14.1%, and
14.1%, respectively, and the interindividual variation of VEGF in serum, whole blood, and
plasma is 47.6%, 28.8%, and 18.1%, respectively (Meo et al., 2005). The greater intraindividual
variability in the whole blood is impacted by the release of VEGF from lymphocytes, granu‐
locytes, monocytes, and megakariocytes, variability also being dependent on the process of
leukocyte lysis, irrespective of the use of standardized methods (Meo et al., 2005) In light of
the potential clinical utility of VEGF in the prognosis, patient selection, and follow-up of anti-
VEFG therapeutic effects, Kong et al., (2008) (49) have constructed the reference intervals for
VEFG in the serum and plasma of the population of the Republic of North Korea using the
ELISA method with R&D Systems reagents. The reference intervals were calculated in 131
subjects, aged 20 to 78 years (68 males and 63 females). Reference intervals differ considerably
in serum and plasma, whereat the values in serum are ten- to twenty eight- fold higher than
those in plasma.
Moreover, plasma concentrations of VEGF depend on the kind of anticoagulant, with the
values being considerably higher when determined by EDTA as an anticoagulant than when
determined using heparin as an anticoagulant. In addition to VEGF, concentrations of Ang-2
and Tie-2 also statistically significantly differ according to gender and kind of material used
(Lieb et al., 2010).
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From among the parameters analyzed, only VEGF showed a statistically significant negative
relationship with age in the control subjects. The Ang-2 concentrations were statistically
significantly higher in the control group females. Other parameters were not statistically
significantly different between male and female subjects of the groups studied.
The levels of VEGF, Ang-2, and Tie-2 determined in the serum of the control group were
within the value range for healthy individuals set out by the manufacturer and other au‐
thors using the same method and reagent from the same manufacturer (Lieb et al., 2010;
Nylaende et al., 2006).
A significant difference in the concentrations of VEGF was found between diabetic and
nondiabetic subjects, with the median concentration of VEGF in diabetics being higher than
that observed in nondiabetic subjects. There was no difference in concentrations of VEGF,
Ang-2, and Tie-2 receptor between smokers and non-smokers, nor between the subjects on
lipolythic and antihypertensive therapy and subjects off therapy.
In the patients with peripheral arterial disease, VEGF significantly correlated with CRP (r=0,45,
P<0.001) and HDL cholesterol (r= - 0,26, P=0,006). Angiopoietin-2 significantly correlated with
CRP (r=0,36, P<0,001), as well as Tie-2 which showed a weak but significant association with
CRP (r=0,25, P=0,008).
Because all three markers of angiogesis correlated with the CRP concentration in the group
studied, compared with the controls, and a correlation between the concentrations of VEGF
and HDL cholesterol was found, we examined whether the concentrations of the biochemical
parameters under study differed depending on the CRP concentration as a cardiovascular risk
factor. The concentrations of HDL- cholesterol, VEGF, Ang-2, and Tie-2 were statistically
significantly different among the subjects with various cardiovascular risk profiles, with the
HDL -cholesterol values being significantly higher in the low risk subjects (CRP<1,0 mg/L)
compared with the moderate (CRP between 1,0-3,0 mg/L) (P=0,004) and high risk (P=0,011)
subjects (CRP >3,0 mg/L). The subject groups of moderate and high cardiovascular risk did
not differ significantly in the HDL cholesterol concentration (P=0,666). Statistically significant
difference was found in the concentrations of VEGF (P=0,011), Ang-2 (P<0,001), and Tie-2
receptor (P=0,005) between low and high risk subjects, as well as in the concentrations of VEGF
(P=0,012), Ang-2 (P<0,001), and Tie-2 receptor (P=0,02) between the moderate and high
cardiovascular risk subjects, whereas there were no statistically significant differences in the
concentrations of VEGF (P=0,377), Ang-2 (P=0,438), and Tie-2 receptor (P=0,673) between the
groups of low and moderate cardiovascular risk subjects. The results are suggestive of an
association between inflammation and angiogenesis in peripheral arterial disease.
In this investigation, no association was found of the biochemical parameters under study,
namely, triglycerides, total, HDL-, LDL-cholesterol, CRP, and novel biomarkers of inflamma‐
tion (PAF-AH) and angiogenesis (VEGF, Ang-2, and Tie-2 receptor) with the angiographic
score as a measure of the anatomic extent of atherosclerotic alterations in the peripheral
arteries.
It has been well documented that inflammation is implicated in all stages of the atherosclerotic
process. The role of CRP, as a nonspecific marker of inflammation and cardiovascular risk
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factor in the development and progression of atherosclerosis, is extensively investigated.
Tzoulaki et al., (2005), in a large prospective trial nested within the Edinburgh Artery Study
confirmed the role of CRP, interleukin-6 (IL-6), and intercellular adhesion molecule (ICAM)
in the progression of peripheral artery disease in the general population. The trial included
1582 individuals, ranging in age 55 to 75 years, and atherosclerotic progression was defined
as reduction in the ankle brachial index (ABI) over the period of 5 and 12 years. In the
investigation of the patients with peripheral arterial disease who had ABI<0.90, the CRP levels
greater than 3.0 mg/L had an additive predictive value to risk assessment for adverse cardio‐
vascular events (Khawaja & Kullo, 2009). Although in the clinical practice, ABI measurement
is considered a simple method of assessing peripheral artery disease progression, and the ABI
values correlate well with the degree of peripheral arterial atherosclerotic changes as measured
using the digital subtraction angiography method, these two methods represent different
aspects of severity assessment of peripheral arterial disease, and cannot be directly compared
( Nylaende et al., 2006). Nylaende et al., (2006) evaluated the relationship between inflamma‐
tory markers and the severity of peripheral artery disease assessed on the basis of the angio‐
graphic score and ABI determined with and without Treadmill test. The study was conducted
in 127 patients, range 45-79 years, with the simptoms of intermittent claudication in whom the
angiographic score was determined based on the angiographic criteria for haemodynamically
significant stenosis. The results of their study demonstrated significant associations of MCP-1,
CD40L, IL-6, and TNF-alpha with the angiographic score contrary to the concentrations of
CRP, IL-10, E-selectin, P-selectin, ICAM-1, and VCAM-1 for which no significant associations
with the angiographic score were observed. ICAM-1 and IL-6 showed a statistically significant
correlation with the maximum walking distance on the treadmill, and neither of the markers
under study correlated with the ABI. Based on the available data, this is the only investigation
into the association between the inflammation marker and the extent of angiographically
detected atherosclerotic alterations in the patients with peripheral aterosclerosis. A substantial
number of studies have investigated the correlation between the marker of inflammation and
the degree of angiographically demonstrated atherosclerotic changes in cerebral and coronary
atherosclerosis. Flegar-Meštrić et al., ( 2007), in a study of 119 patients, age range between 43
and 80 years, with stenosis of extracranial cerebral arteries found a significant association
between the CRP level and stenotic extent greater than 70% compared with the control group
with normal-appearing cerebral arteries on ultrasonography. The association with CRP of
angiographically confirmed coronary atherosclerosis is controversial. Coronary disease and
CRP are considered to independently and additively contribute to the risk for adverse
cardiovascular events. Angiographic imaging seems to detect stable and instable plaques, and
the value of CRP lies in its ability to predict myocardial infarction or fatal outcome independ‐
ently of the result of angiography (Niccoli et al., 2008; Geluk et al., 2008). Niccoli et al., (2008),
in an investigation of 97 patients with unstable angina, failed to demonstrate any correlation
between the basal CRP values and the severity of angiographic changes. In a prospective study
within the Prevention of Renal and Vascular Endstage Disease (PREVEND) trial, including
8,139 individuals with no presence of coronary artery disease, Geluk et al., (2008) found weak
correlations between the basal CRP concentrations and the degree of alterations demonstrated
on angiogram in 216 patients who developed coronary disease over a 5-year period.
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In our investigation, we found no evidence of associations between the CRP level and the
extent of peripheral arterial changes on angiography, which is consistent with the results by
Nylaende M. et al. (2006). It is also possible that some of the biomarkers for which a difference
in concentrations between the groups studied has been found are involved in other mecha‐
nisms of vascular homeostasis regulation, and that they have importance in earlier phases of
development of peripheral arterial atherosclerotic changes, which evade detection by the
digital subtraction angiography method.
5. Conclusion
This study confirmed the role of hypertriglyceridemia and CRP as risk factors in the develop‐
ment of peripheral arterial disease. Lower concentrations of HDL cholesterol in patients could
indicate its reduced protective role in preventing the atherogenic process. PAF-AH can not be
considered a reliable diagnostic indicator of peripheral arterial disease since the changes in
enzyme activity may reflect the altered lipid parameters. Correlation between the CRP
concentrations and the concentrations of VEGF, Ang-2 and its receptor Tie-2 appears to suggest
an association between inflammation and angiogenesis in the development of peripheral
arterial disease. An increased concentration of Ang-2 and Tie-2 receptor could indicate
increased vascular remodeling in response to the presence of risk factors and could be
considered new biomarkers of angiogenesis which indicate the presence of peripheral arterial
disease. The absence of significant correlation between the concentrations of the biochemical
parameters investigated and the angiographic score suggests that other factors play a more
important role in the progression of the disease. Further research is needed on larger groups
of subjects to confirm the value of PAF-AH, VEGF, Ang-2 and Tie-2 receptor, as new diagnostic
indicators of atherosclerosis of peripheral arteries.
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Paraoxonase Polymorphisms and Platelet Activating Factor Acetylhydrolase Activity
as a Genetic Risk Factors in Cerebral Atherosclerosis. In: Parthasarathy S. (Ed.) Athe‐
rogenesis, Rijeka: InTech, 2012. p507-528., Available from: http://www.intechop‐
en.com/books/atherogenesis/ paraoxonase-polymorphisms - and- platelet-activating-
factor-acetylhydrolase-activity-as-a-genetic-risk-(accessed 25-April 2012).
Current Trends in Atherogenesis116
[21] Fukuhara, S.; Sako, K.; Noda, K.; Zhang, J.; Minami, M.; Mochizuki N. (2010). Angio‐
poietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis. Histology
and Histopathology, Vol.25, No.3, pp. 387-396, ISSN: 0213-3911
[22] Garza, CA.; Montori, VM.; McConnell, JP.; Somers, VK.; Kullo IJ. & Lopez-Jimenez,
F. (2007). Association between lipoprotein-associated phospholipase A2 and cardio‐
vascular disease: a systematic review. Mayo Clinic Proceedings, Vol.82, No.2, (Febru‐
ary 2007), pp. 159–65, ISSN 0025-6196
[23] Gazi, I.; Lourida, ES.; Filippatos, T.; Tsimihodimos, V.; Elisaf, M. & Tselepsis, AD.
(2005). Lipoprotein-associated phospholipase A2 Activity Is a Marker of Small,
Dense LDL Particles in Human Plasma. Clinical Chemistry, Vol.51, No.12, pp.
2264-2273, ISSN:0009-9147
[24] Geluk, CA.; Post, W.J.; Hillege, HL.; Tio, RA.; Tijssen, JG.; van Dijk, RB.; Dijk, WA.;
Bakker, SJ.; de Jong PE.; van Gilst, WH.; Zijlstra, F. (2008). C-reactive protein and an‐
giographic characteristics of stable and unstable coronary artery disease: data from
the prospective PREVEND cohort. Atherosclerosis, Vol. 196, pp. 372- 382, ISSN:
0021-9150
[25] Hoeben, A.; Landuy, TB.; Highley, MS.; Wildiers, H.; Van Oosterom, AT. & De
Bruijn, EA. (2004). Vascular Endothelial Growth Factor and Angiogenesis. Pharmaco‐
logical Reviews, Vol.56, pp. 549-580 ISSN:1521-0081
[26] Iribarren, C. (2010). Lipoprotein-Associated Phospholipase A2 and C-Reactive Pro‐
tein for Measurement of Inflammatory Risk: Independent or Complementary? Cur‐
rent Cardiovascular Risk Reports, Vol. 4, pp. 57-67,ISSN: 1932-9520
[27] Kamisako, T.; Takeuchi, K.; Ito, T.; Tamaki, S.; Kosaka, T.; Adachi, Y. (2003). Serum
platelet - activating factor acetylhydrolase (PAF-AH) activity in patients with hyper‐
bilirubinemic hepatobiliary disease. Hepatology Research, Vol. 26, pp. 23-27, ISSN :
1386-6346
[28] Khawaja, FJ. & Kullo, IJ. (2009). Novel markers of peripheral arterial disease. Vascular
Medicine, Vol. 14, pp. 381-392,ISSN: 1358-863X
[29] Koenig, W.; Khuseyinova, N.; Löwel, H.; Trishler, G .& Meisinger, C. (2004). Lipopro‐
tein associated phospholipase A2 adds to risk prediction of incident coronary events
by C-reactive protein in apparently healthy middle-aged men from the general popu‐
lation: results from the 14–year follow-up of a large cohort from southern Germany.
Circulation, Vol. 110, No. 14, (October 2004) pp. 1903-1908, ISSN 0009-7322
[30] Kong, ASY.; Lee, HL.; Eom, HS.; Park, WS.; Yun, T.; Kim, HJ. et al. (2008). Reference
intervals for circulating angiogenic cytokines. Clinical Chemystry and Laboratory Medi‐
cine, Vol. 46, pp. 545-550,ISSN: 1434-6621
The Evaluation of New Biomarkers of Inflammation and Angiogenesis in Peripheral Arterial Disease
http://dx.doi.org/10.5772/53341
117
[31] Kosaka, T.; Yamaguchi, M.; Soda, Y.; Kishimoto, T.; Tago, A.; Toyosato, M. et al.
(2000). Spectrophotometric assay for serum platelet-activating factor acetylhydrolase
activity. Clinica Chimica Acta, Vol.296, No.1-2., pp. 151–161, ISSN:009 - 8981
[32] Lee KW, Lip GY, Blann AD. (2004). Plasma angiopoietin-1, angiopoietin-2, angio‐
poietin receptor Tie-2, and vascular endothelial growth factor levels in acute coro‐
nary syndromes. Circulation., Vol. 110, pp. 2355-2360, ISSN: 0009-7322
[33] Li, J.; Li, JJ.; Li, Q.; Li, Z. & Qian, HY. (2007). A rational connection of inflammation
with peripheral arterial disease. Medical Hypotheses, Vol.69, pp. 1190-1195, ISSN:
0021-9150
[34] Lieb, W.; Zachariah, JP.; Larson, MG.; Vasan, RS.; Smith, HM.; Sawyer, DB. et al.
(2010). Clinical and genetic correlates of circulating angiopoietin-2 and soluble Tie-2
in the community. Circulation: Cardiovascular Genetics, Vol. 3, No. 3., pp. 300-306,
ISSN:1942-325X
[35] Lim, HS.; Blann, AD.; Chong, AY.; Freestone, B.; Lip, GYH. (2004). Plasma Vascular
Endothelial Growth Factor, Angiopoietin-1, and Angiopoietin-2 in Diabetes Implica‐
tions for cardiovascular risk and effects of multifactorial intervention. Diabetes Care,
Vol. 27, pp. 2918-2924,ISSN :0149-5992
[36] Meo, S.; Dittadi, R.& Gion, M. (2005). Biological variation of vascular endothelial
growth factor. Clinical Chemystry and Laboratory Medicine, Vol. 42, pp. 342-343,ISSN:
0785-3890
[37] Meru, AV.; Mittra, S.; Thyagarajan, B.; Chugh, A. (2006). Intermittent claudication:
An overview. Atherosclerosis, Vol.187, pp. 221-237, ISSN: 0021-9150
[38] Münzel, T. & Gori, T. Lipoprotein-associated phospholipase A2, a marker of vascular
inflammation and systemic vulnerability. European Heart Journal, Vol.30, No.23, (De‐
cember 2009), pp. 2829-2831, ISSN 1520-765X
[39] Niccoli, G.; Biasucci LM., Biscione, C.; Fusco, B., Porto, I., Leone, AM. et al. (2008).
Independent prognostic value of C-reactive protein and coronary artery disease ex‐
tent in patients affected by unstable angina. Atherosclerosis, Vol. 196, pp. 779-785,
ISSN: 0021-9150
[40] Nylaende, M.; Kroese, A.; Stranden, E.; Morken, B.; Sandbaek, G.; Lindahl, AK. et al.
(2006). Markers of vascular inflammation are associated with the extent of atheroscle‐
rosis assessed as angiographic score and treadmill walking distances in patients with
peripheral arterial occlusive disease. Vascular Medicine, Vol. 11, pp. 21-28, ISSN:
1358-863X
[41] Olsson, AK.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. (2006). VEGF receptor sig‐
nalling - in control of vascular function. Nature Reviews Molecular Cell Biology, Vol.7,
pp. 359-371, ISSN:1471-0080
Current Trends in Atherogenesis118
[42] Otrock, ZK.; Mahfouz, RA.; Makarem, JA.; Shamseddine AI. (2007). Understanding
the biology of angiogenesis: Review of the most important molecular mechanisms.
Blood Cells, Molecules, and Diseases, Vol.39, pp. 212-220, ISSN: 1079-9796
[43] Patel, JV.; Lim, HS.; Varughese, GI.; Hughes, EA. & Lip, GYH. (2008). Angiopoietin-2
levels as a biomarker of cardiovascular risk in patients with hypertension. Annals of
Medicine, Vol. 40, pp. 215-222, ISSN: 0785-3890
[44] Perkov, S.; Kardum Paro, MM.; Šiftar, Z.; Grga, A.; Vidjak, V; Novačić, K. et al.
(2010). Biomarkers of inflammation in patients with angiographically assessed pe‐
ripheral arterial disease (abstract). First European Joint Congress of EFCC and UEMS,
Lisabon, Portugal, October 13-16, P16-5, pp. 149, ISSN :
[45] Resnick, HE.; Lindsay, RS., McDermott, MM.; Devereux, RB., Jones, KL.; Fabsitz, RR.
et al. (2004). Relationship of high and low ankle brachial index to all-cause and cardi‐
ovascular disease mortality: the Strong Heart Study. Circulation, Vol.109, pp. 733-739,
ISSN: 0009-7322
[46] Rey, S. & Semenza, GL. (2010). Hypoxia-inducible factor-1-dependent mechanisms of
vascularization and vascular remodelling. Cardiovascular Research, Vol.86, pp.
236-242, ISSN:0008-6363
[47] Sharma, AM. & Aronow, HD. (2012). Lower Extremity Peripheral Arterial Disease.
In: Gaxiola E. (Ed.) Traditional and Novel Risk Factors in Atherothrombosis. Rijeka: In‐
Tech, 2012.p119-40.Available from: http://www.intechopen.com/books/traditional-
and-novel-risk-factors-in-atherothrombosis/lower-extremity-peripheral-arterial-
disease (accessed 25-August 2012).
[48] Scharpfenecker, M.; Fiedler, U.; Reiss, Y.; Augustin, HG. (2004). The Tie-2 ligand An‐
giopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop
mechanism. Journal of Cell Science, Vol.118, No.4, pp. 771-780 ISSN: 0021- 9533
[49] Shireman, PK. (2007). The chemokine system in arteriogenesis and hind limb ische‐
mia. Journal of Vascular Surgery, Vol.45 Suppl A, pp. A48-A56, ISSN: 0741-5214
[50] Silvestre, J-S.; Mallat, Z. Tedgui, A. & Lévy BI. (2008). Post-ischaemic neovasculariza‐
tion and inflammation. Cardiovascular Research, Vol.78, No.2., pp. 242-249 ISSN:
0008-6363
[51] Srinivasan, P. & Bahnson, BJ. (2010) Molecular Model of Plasma PAF Acetylhydro‐
lase-Lipoprotein Association: Insights from the Structure. Pharmaceuticals, Vol. 3, pp.
541-557, ISSN 1424-8247
[52] Stuttfeld, E. & Ballmer-Hofer, K. (2009). Structure and Function of VEGF Receptors.
IUBMB Life, Vol.61, No.9, pp. 915-922, ISSN: 1521-6543
[53] Tzoulaki, I.; Murray, GD.; Lee, AJ.; Rumley, A.; Lowe, GDO. & Fowkes, GR. (2005).
C-Reactive Protein, Interleukin-6, and Soluble Adhesion Molecules as Predictors of
The Evaluation of New Biomarkers of Inflammation and Angiogenesis in Peripheral Arterial Disease
http://dx.doi.org/10.5772/53341
119
Progressive Peripheral Atherosclerosis in the General Population. Circulation, Vol.
112, pp. 976- 983,ISSN:0009-7322
[54] Tsimikas, S.; Tsironis, LD. & Tselepsis, AD. (2007). New Insights Into the Role of Lip‐
oprotein (a)-Associated Lipoprotein-Associated Phospholipase A2 in Atherosclerosis
and Cardiovascular Disease. Arteriosclerosis Thrombosis and Vascular Biology, Vol.27,
No.10, (October 2007), pp. 2094-2099, ISSN 1079-5642
[55] Zalewski, A. & Macphee, C. (2005). Role of Lipoprotein-Associated Phospholipase
A2 in Atherosclerosis Biology, Epidemiology, and Possible Therapeutic Target. Arte‐
riosclerosis, Thrombosis and Vascular Biology, Vol.25, No.5, (May 2005), pp. 923- 931,
ISSN 1049-8834
[56] Winkler, K.; Winkelmann, BR.; Scharnagl, H.; Hoffmann, MM.; Grawitz, AB.; Nauck,
M. et al. (2005). Platelet-Activating Factor Acetylhydrolase Activity Indicates Angio‐
graphic Coronary Artery Disease Independently of Systemic Inflammation and Oth‐
er Risk Factors: The Ludwigshafen Risk and Cardiovascular Health Study.
Circulation, Vol. 111, No.8, pp. 980-987,ISSN :0009-7322
Current Trends in Atherogenesis120
